Last reviewed · How we verify
Placebo plus best supportive care
Placebo plus best supportive care provides no active pharmacological intervention, serving as a control arm to evaluate the efficacy of investigational treatments.
At a glance
| Generic name | Placebo plus best supportive care |
|---|---|
| Sponsor | Shanghai Miracogen Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This is a control comparator used in clinical trials, not an active drug. It consists of an inert placebo combined with standard-of-care supportive measures (symptom management, monitoring, etc.). The purpose is to establish a baseline for measuring the true benefit of the investigational drug being tested against it.
Approved indications
Common side effects
Key clinical trials
- A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia (PHASE2)
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant (PHASE3)
- Phase II Study of Regorafenib as Maintenance Therapy (PHASE2)
- Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma (PHASE2)
- A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) (PHASE2, PHASE3)
- A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission (PHASE2)
- A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) (PHASE3)
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo plus best supportive care CI brief — competitive landscape report
- Placebo plus best supportive care updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI